Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences
Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with the Brush and Key Foundation, announced the publication…
-
QualityStocksNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Demonstrates DefendAir Counter-UAS System at Israel Defense Ministry Event
ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company focused on autonomous solutions for manned and…
-
QualityStocksNewsBreaks – GlobalTech Corp. (OTC: GLTK) Names D. Boral Capital as Strategic Advisor for Planned Moda in Pelle Acquisition
GlobalTech (OTC: GLTK), a U.S.-headquartered technology holding company focused on artificial intelligence, big data and…